Carolinas HealthCare System

Research and Clinical Trials

Title  
EVOLVE Short-DAPT
Brief Description  
The EVOLVE Short DAPT study is a prospective, single-arm study designed to assess the safety of 3-month DAPT in patients at high risk for bleeding, undergoing percutaneous coronary intervention with a SYNERGY stent system. All partiicpants must be treated with aspirin for the duration of the study and must also be treated with either clopidogrel, prasugrel, or ticagrelot for the 3 months following the procedure.
Who may be Eligible  
Patients at high risk for bleeding who have had implantation of at least one SYNERGY stent within the preceding 3 calendar days.
Start Date  
07/19/2016
IRB Number  
05-16-02A
Principal Investigator  
Rinaldi, Michael
Contact Name  
Sally

For More Information, Contact   Sally  Krueger , RN
Phone:  (704) 355-4797  Fax:  (704) 355-7264 
Email:  SHVIClinicalResearch@carolinashealthcare.org
Address:  1001 Blythe Blvd, MCP-M-201
Charlotte, NC 28203
Close